Last $4.89 USD
Change Today -0.0119 / -0.24%
Volume 61.8K
ALXA On Other Exchanges
As of 1:53 PM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

alexza pharmaceuticals inc (ALXA) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/25/14 - $5.93
52 Week Low
04/14/14 - $3.92
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

alexza pharmaceuticals inc (ALXA) Related Businessweek News

No Related Businessweek News Found

alexza pharmaceuticals inc (ALXA) Details

Alexza Pharmaceuticals, Inc., a pharmaceutical company, focuses on the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions worldwide. The company’s product candidates are based on a proprietary technology, the Staccato system, which vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. Its lead product, ADASUVE (Staccato loxapine) inhalation powder for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. The company’s product candidate in development, AZ-002 (Staccato alprazolam), is indicated for the treatment of acute repetitive seizures. It has strategic collaborations with Grupo Ferrer Internacional S.A. and Teva Pharmaceuticals USA, Inc. The company was formerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005. Alexza Pharmaceuticals, Inc. was incorporated in 2000 and is based in Mountain View, California.

90 Employees
Last Reported Date: 03/25/14
Founded in 2000

alexza pharmaceuticals inc (ALXA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $526.0K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $384.3K
Compensation as of Fiscal Year 2013.

alexza pharmaceuticals inc (ALXA) Key Developments

Alexza Pharmaceuticals Inc. Promotes Edwin S. Kamemoto to Senior Vice President, Regulatory Affairs

Alexza Pharmaceuticals Inc. announced the promotion of Edwin S. Kamemoto, Ph.D., to the newly created position of Senior Vice President, Regulatory Affairs. Dr. Kamemoto will have primary responsibility for leading and directing all regulatory affairs and global pharmacovigilence activities. Dr. Kamemoto has been Alexza's Vice President, Regulatory Affairs since July 2012. He joined Alexza in 2006 as Associate Director, Regulatory Affairs, was promoted to Director, Regulatory Affairs in 2007, to Senior Director, Regulatory Affairs in 2008, and to Executive Director, Regulatory Affairs in 2010.

Alexza Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

Alexza Pharmaceuticals Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported revenue of $2,166,000 against $729,000 a year ago. Loss from operations was $8,803,000 against $9,603,000 a year ago. Net loss was $10,735,000 or $0.62 per basic and diluted share against $20,712,000 or $1.31 per basic and diluted share a year ago.

Alexza Pharmaceuticals Reports Availability of ADASUVE in the Nordic Countries for Schizophrenia or Bipolar Disorder

Alexza Pharmaceuticals announced the market launch of ADASUVE inhalation powder, pre-dispensed (loxapine) in the Nordic countries (Sweden, Norway, Denmark and Finland) for the treatment of schizophrenia or bipolar disorder.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALXA:US $4.89 USD -0.0119

ALXA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $45.99 USD +1.30
Aradigm Corp $8.52 USD +0.02
Dr Reddy's Laboratories Ltd 2,823 INR +53.45
Durect Corp $1.50 USD -0.02
Endo International PLC $67.54 USD +0.88
View Industry Companies

Industry Analysis


Industry Average

Valuation ALXA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALEXZA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at